Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: A strategy for enhancing the specific antitumor effect of marrow grafts

Blood

Volumn 87, Issue 7, 1996, Pages 3053-3060

  Kwak, Larry W ^a   Pennington, Robin ^b   Longo, Dan L ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN IDIOTYPE;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; B CELL LYMPHOMA; BONE GRAFT; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; IMMUNE RESPONSE; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; MULTIPLE MYELOMA; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL;

EID: 0030002018     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.7.3053.bloodjournal8773053     Document Type: Article

References (36)

1. Jones RJ, Ambinder RF, Piantadosi S, Santos GW: Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649, 1991
2. Demirer T, Weaver CH, Buckner CD, Petersen FB, Bensinger WI, Sanders J, Clift RA, Lilleby K, Anasetti C, Martin P, Storb R, Chauncey T, Doney K, Sullivan K, Appelbaum FR: High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. J Clin Oncol 13:596, 1995
3. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, Facon T, Granena A, Gore M, Gratwohl A, Lowenberg B, Nikoskelainen J, Reiffers JJ, Samson D, Verdonck L, Volin L: Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 325:1267, 1991
4. Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, Mehra R, van Besien K, Delasalle KB, Reading C, Deisseroth AB, Champlin RE: Thiotepa, busulfan, and cyclophosphamide: A new preparative regimen for autologous blood stem cell transplantation in high-risk multiple myeloma. Blood 82:2324, 1993
5. Weiden PL, Sullivan K, Flournoy N, Storb R, Thomas ED, The Seattle Marrow Transplant Team: Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529, 1981
6. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990
7. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462, 1990
8. Kohler PC, Hank JA, Exten R, Minkoff DZ, Wilson DG, Sondel PM: Clinical response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes. A case report and phase I trial. Cancer 55:552, 1985
9. Starling KA, Falletta JM, Fernbach DJ: Immunologic chimerism as evidence of bone marrow graft acceptance in an identical twin with acute lymphocytic leukemia. Exp Hematol 3:244, 1975
10. Lum LG, Seigneuret MC, Storb R: The transfer of antigen-specific humoral immunity from marrow donors to marrow recipients. J Clin Immunol 6:389, 1986
11. Wimperis JZ, Prentice HG, Karayiannis P, Brenner MK, Reittie JE, Griffiths PD, Hoffbrand AV: Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1:339, 1986
12. Kato S, Yabe H, Yabe M, Kimura M, Ito M, Tsuchida F, Tsuji K, Takahashi M: Studies on transfer of varicella-zoster-virus specific T-cell immunity from bone marrow donor to recipient. Blood 75:806, 1990
13. Wimperis JZ, Gottlieb D, Duncombe AS, Heslop HE, Prentice HG, Brenner MK: Requirements for the adoptive transfer of antibody responses to a priming antigen in man. J Immunol 144:541, 1990
14. Rouleau M, Senik A, Leroy E, Vernant J-P: Long-term persistence of transferred PPD-reactive T cells after allogeneic bone marrow transplantation. Transplant 55:72, 1993
15. Sirisinha S, Eisen HN: Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci USA 68:3130, 1971
16. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN: Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci USA 69:1540, 1972
17. Freedman PM, Autry JM, Tokuda S, Williams RC Jr: Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein. J Nat Cancer Inst 56:735, 1976
18. George AJT, Tutt AL, Stevenson FK: Anti-idiotypic mechanisms involved in suppression of a mouse B-cell lymphoma, BCL1. J Immunol. 138:628, 1987
19. Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R: Idiotype vaccination against murine B-cell lymphoma. Humoral and cellular requirements for the full expression of anti-tumor immunity. J Immunol 145:1029, 1990
20. Kwak LW, Campbell MJ, Czerwinski D, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209, 1992
21. Hornung RL, Longo DL, Bowersox OC, Kwak LW: Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor. J Natl Cancer Inst 87:1289, 1995
22. Bergman Y, Haimovich J: Characterization of a carcinogen induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol 7:413, 1977
23. Eshhar Z, Blatt C, Bergman Y, Haimovich J: Induction of secretion of IgM from cells of the B cell line 38C13 by somatic cell hybridization. J Immunol 122:2430, 1979
24. Wang E, Conant JM, Li D, Visconti V, Chourmouzis E, Lau C: Ex vivo spermine dialdehyde treatment prevents lethal GVHD in a murine bone marrow transplantation model. Bone Marrow Transplant 6:235, 1990
25. Siu H, Vitetta ES, May RD, Uhr JW: Regression of BCL1 tumor and induction of a dormant tumor state in mice chimeric at the major histocompatibility complex. J Immunol 137:1376, 1986
26. Blazar BR, Taylor PA, Sehgal SN, Vallera DA: Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow. Blood 83:600, 1994
27. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hofman RG, Jacobsen SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk for relapse associated with T-cell depletion. Ann Intern Med 108:806, 1988
28. Marmont A, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzig RH, Hong R, Masaoka T, Rimm AA, Ringen O, Speck B, Weiner R, Bortin MM: T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120, 1991
29. Sullivan KM, Storb R, Buckner CD, Feter A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J, Martin P, Sanders JE, Singer J, Thomas ED: Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320:828, 1989
30. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, Horowitz MM, Flomenberg N: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 82:2310, 1993
31. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100, 1994
32. Samlowski WE, Araneo BA, Butler MO, Fung MC, Johnson HM: Peripheral lymph node helper T-cell recovery after syngeneic bone marrow transplantation in mice prepared with either γ-irradiation or busulfan. Blood 74:1436, 1989
33. Daley MJ, Gebel HM, Lynch RG: Idiotype-specific transplantation resistance to MOPC-315: Abrogation by post-immunization thymectomy. J Immunol 120:1620, 1978
34. Heber-Katz E, Schwartz RH, Matis LA, Hannum C, Fairwell T, Appella E, Hansburg D: Contribution of antigen-presenting cell major histocompatibility complex gene products to the specificity of antigen-induced T cell activation. J Exp Med 155:1086, 1982
35. Lauritzsen GF, Bogen B: The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. Cell Immunol 148:177, 1993
36. Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL: Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 345:1016, 1995